Go online to PeerView.com/WPW860 to view the entire program with slides. In this activity, an expert in multiple myeloma discusses newer safety and efficacy data surrounding novel and emerging therapeutic drug classes for multiple myeloma, including agents directed against intracellular targets and immune-based treatment. The activity will also include expert insights on how to develop effective, individualized treatment strategies with novel components that are informed by clinical findings and how to manage treatment-related adverse effects associated with emerging agent classes. Upon completion of this activity, participants should be better able to: Cite updated data about the efficacy and safety of novel agent classes and next-generation therapeutics in multiple myeloma, including proteasome inhibitors, IMiDs, novel antibodies, immunotherapies, and epigenetic agents, among others, Develop customized therapy for patients with newly diagnosed multiple myeloma, including elderly patients, individuals eligible or ineligible for stem-cell transplant, and those requiring maintenance therapy post-transplant, Select regimens adapted to the needs of patients with previously treated multiple myeloma, including those with early relapse or relapsed/refractory multiple myeloma, Manage treatment-related adverse events in patients with multiple myeloma receiving therapy with novel or next-generation agent classes.
View all episodes
